The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Fei Cao†, Yi Yang‡, Tongguo Si†, Jun Luo†, Hui Zeng†, Zhewei Zhang†, Duiping Feng‡, Yi Chen‡* and Jiaping Zheng†*

1 Department of Interventional Radiology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China, 2 Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3 Key Laboratory of Gene Editing Screening and Research and Development (R&D) of Digestive System Tumor Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 4 Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China, 5 Department of Interventional Radiology, First Hospital of Shanxi Medical University, Taiyuan, China

Objective: To assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC).

Patients and Methods: The data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus sintilimab were retrospectively assessed. Patients received lenvatinib orally once daily 2 weeks before TACE, followed by sintilimab administration at 200 mg intravenously on day 1 of a 21-day therapeutic cycle after TACE. The primary endpoints were objective response rate (ORR) and duration of response (DOR) by the modified RECIST criteria.

Results: Median duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). ORR was 46.7% (28/60). Median DOR in confirmed responders was 10.0 months (95%CI 9.0-11.0 months). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months).

Conclusions: TACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma.

Keywords: hepatocellular carcinoma, transarterial chemoembolization, targeted therapy, immunotherapy, comprehensive therapy
INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors and the fourth leading cause of cancer-related death worldwide (1). In patients with early-stage HCC, ablation, resection and transplantation have been recommended as curable therapies (2). Although unresectable disease may be treated by transarterial chemoembolization (TACE) and systemic therapy, most patients have a poor prognosis (3).

According to the Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy, TACE represents the standard treatment option for patients with intermediate stage HCC (4), being associated with longer survival compared with best supportive care (5). Meanwhile, only TACE hardly improves survival in advanced HCC (6, 7).

Lenvatinib has become a first-line systemic therapeutic option for advanced HCC (3, 4). In the phase III REFLECT trial (8), lenvatinib was non-inferior to sorafenib in overall survival (OS), showed greater objective response rate (ORR) and median progression-free survival (PFS), and conferred hepatic function in advanced HCC (9, 10).

Immune checkpoint inhibitors, as immunotherapeutic agents, have shown promising outcomes in patients with advanced HCC (11). In the KEYNOTE-240 study, although OS and PFS did not reach statistical significance, ORR and overall response were better than those of placebo, and some patients benefited from pembrolizumab (12). Sintilimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to the PD-1 molecule on the surface of T cells, consequently blocking the tumor immune tolerance-inducing PD-1/programmed death-ligand 1 (PD-L1) pathway, re-activating the anti-tumor activities of lymphocytes, and inhibiting tumors. Sintilimab has been approved for marketing in December 2018, mainly for the treatment of recurrent or refractory classical Hodgkin lymphoma previously treated with at least two lines of chemotherapy. Sintilimab is also been applied for the treatment of various solid tumors in clinical practice, including lung cancer, liver cancer, and esophageal cancer, with notable safety and high efficacy.

Combination therapies have been researched for liver cancer, with favorable results (13), including PD-1 inhibitors plus lenvatinib, TACE plus Sorafenib and TACE plus Lenvatinib (14, 15). However, to date, TACE combined with lenvatinib plus sintilimab has not been studied for patients with unresectable HCC. Therefore, we conducted this retrospective study to assess the efficacy and safety of TACE combined with lenvatinib plus sintilimab in unresectable HCC.

PATIENTS AND METHODS

Patients

In this retrospective study, the medical records and imaging data of HCC patients were obtained at the Cancer Hospital of the University of Chinese Academy of Sciences, Tianjin Medical University Cancer Institute and Hospital, and First Hospital of Shanxi Medical University between January 2019 and March 2021. All patients were diagnosed with HCC by non-invasive criteria or biopsy. The non-invasive diagnostic criteria for HCC in patients with cirrhosis were: liver cirrhosis; tumor diameter larger than 1 cm based on four-phase multi-detector computed tomography (MDCT) or dynamic magnetic resonance imaging (MRI), and arterial hypervascularization with venous or delayed phase washout (16, 17). Inclusion criteria were: [1] BCLC B or C stage; [2] at least one measurable target lesion; [3] Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-1; [4] Child-Pugh class A score of 5-6. Exclusion criteria were: [1] prior systemic therapy or immunotherapy; [2] follow up <6 months; [3] a history of autoimmune disease. This study was approved by the Ethics Committees of the Cancer Hospital of the University of Chinese Academy of Sciences, Tianjin Medical University Cancer Institute and Hospital, and First Hospital of Shanxi Medical University. All patients were required to provide written informed consent before inclusion in the study.

TACE

TACE was performed by interventional radiologists (F.C, J.Z, T.S, Y.C) with more than ten years of experience. After puncturing the femoral artery, celiac trunk and superior mesenteric artery angiography were performed selectively with a 5F catheter (RH catheter; Cook, Bloomington, Ind). When the tumor-feeding arteries were found, the catheter was advanced into them one by one; a 3F microcatheter (SP microcatheter; Terumo, Tokyo, Japan) was used for selective catheterization if necessary. Oxaliplatin (75 mg/m²) was infused via the catheter, and iodized oil (Lipiodol Ultrafluid; Guerbet, Aulnay-sous-Bois, France) mixed with epirubicin (30-50 mg/m²) was used to embolize tumor-feeding arteries. The TACE procedure was repeated 4-6 weeks later.

Systemic Therapy

Patients received lenvatinib at 12 mg (bodyweight >60 kg) or 8 mg (bodyweight < 60 kg) orally once daily 2 weeks before TACE (6). Patients were administered sintilimab at 200 mg intravenously on day 1 of a 21-day therapy cycle after the TACE procedure.

Follow-Up Visits

Follow-up visits were performed 4-6 weeks after the TACE procedure. The patients underwent chest CT, abdomen multiphase CT or MRI, and laboratory examinations during each follow-up visit. The laboratory examinations encompassed liver function tests, including bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin (ALB) and γ-glutamyl transpeptidase (γ-GT) level assessment, along with prothrombin time (PT) and serum α-fetoprotein (AFP) level evaluation. OS was defined as the time from the first TACE treatment to death or the last follow-up. PFS was defined as the time from the first TACE treatment to disease recurrence or the last follow-up. Intrahepatic tumor progression (25% increase from baseline) and transient deterioration of liver function to Child-Pugh C, macrovascular invasion (MVI) or extrahepatic metastasis was considered to indicate disease progression (6).
Statistical Analysis
Primary endpoints were objective response rate (ORR) and duration of response (DOR) determined by the modified RECIST criteria. The Kaplan-Meier method was used to estimate DOR, PFS and OS. Patients with confirmed complete response (CR) or partial response (PR) were analyzed for DOR. All statistical analyses were performed with SPSS version 23.0.

RESULTS
Patient Demographics
Totally 60 patients were enrolled in the current study between January 2019 and March 2021. Six individuals were excluded because of prior sorafenib or lenvatinib or PD-1 treatment, and two were excluded for follow up <6 months; finally, 52 patients were analyzed (40 patients from Cancer Hospital of the University of Chinese Academy of Sciences, 6 patients from Tianjin Medical University Cancer Institute and Hospital, and 6 patients from First Hospital of Shanxi Medical University). Age, gender, Child-Pugh class, hepatitis B virus (HBV) infection ratio, alpha fetoprotein (AFP) levels, albumin-bilirubin (ALBI) score, baseline characteristics of the 60 patients were collected before therapy (Table 1).

Efficacy
Median duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). Tumor assessments were based on the mRECIST criteria. Objective Response Rate (ORR) was 46.7% (28/60), with complete response (CR) and partial response (PR) observed in 4 and 24 patients, respectively. Twenty-three patients were rated as stable disease (SD), and nine had progressive disease (PD). Reductions of tumor size are shown in Figure 1. Median duration of response (DOR) for confirmed responders was 10.0 months (95%CI 9.0-11.0 months, Figure 2). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months, Figure 3). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months, Figure 4). A patient was evaluated as CR after treating with TACE combined with lenvatinib plus sintilimab as shown in Figures 5A1–5D2.

Safety
Totally 44 patients (84.6%) showed adverse events (AEs) of any grade (Table 2). The most common treatment-related AEs were fatigue (30.8%), hypertension (25%), diarrhea (19.2%), decreased appetite (23%) and Palmar-plantar erythrodysesthesia (21%).

During the study, 48% of patients showed grade 3 AEs [n=25], with hypertension as the most common grade 3 event (24%); 5.7% of patients had grade 4 AEs [n=3]. Totally 3.8% of patients developed grade 5 AEs, including abnormal liver function (n=1) and alimentary tract hemorrhage (n=1). A total of 11.5% (n=6) of patients discontinued any treatment component because of adverse events; one patient died from treatment related alimentary tract hemorrhage on day 134.

TABLE 1 | Baseline characteristics of the 52 patients.

| Characteristic | NO.(%)         |
|----------------|----------------|
| Age (years)    |                |
| ≤65            | 40 (76.9%)     |
| >65            | 12 (23.1%)     |
| Gender         |                |
| Female         | 7 (13.6%)      |
| Male           | 45 (86.4%)     |
| HBV infection  |                |
| Yes            | 47 (90.4%)     |
| No             | 5 (9.6%)       |
| Child-Pugh score |          |
| A              | 46 (88.5%)     |
| B              | 6 (11.5%)      |
| AFP (ng/mL)    |                |
| ≤400           | 34 (65.4%)     |
| >400           | 18 (34.6%)     |
| ALBI score     |                |
| 1              | 10 (19.2%)     |
| 2              | 40 (77.0%)     |
| 3              | 2 (3.8%)       |
| ECOG- PS       |                |
| 0              | 7 (13.5%)      |
| 1              | 45 (86.5%)     |
| BCLC stage     |                |
| B              | 13 (25.0%)     |
| C              | 39 (75.0%)     |
| Macroscopic vascular invasion | |
| lung           | 19 (36.5%)     |
| nodes          | 21 (40.4%)     |
| bone           | 10 (19.2%)     |
| other          | 5 (9.6%)       |
| Extrahepatic site |         |

DISCUSSION
Therapeutic options for unresectable HCC have been developed rapidly in recent years. Sorafenib was the only available systemic therapeutic over a decade ago, and lenvatinib has also become a first–line systemic therapeutic agent for advanced HCC after the REFLECT trial (18). Although immune checkpoint inhibitors alone do not achieve a very significant effect, the combination of immunotherapy and systemic therapy could be very satisfactory. In a phase Ib study, lenvatinib plus pembrolizumab showed promising results in patients with unresectable HCC (19). In this study the ORR reached 46.0% and 36.0% by the mRECIST and RECIST 1.1 criteria, respectively. Median DORs were 8.6 months by mRECIST and 12.6 months by RECIST v1.1. Median overall survival was 22 months. In the IMBrave150 trial (20), atezolizumab plus bevacizumab showed significantly better OS and PFS compared with sorafenib in patients with unresectable HCC. In this study, OS rates at 12 months were 67.2% and 54.6% with atezolizumab plus bevacizumab and sorafenib alone, respectively; median PFS times were 6.8 months and 4.3 months, respectively. Although the exact mechanism of this combination therapy is uncertain, it is possible that VEGF may play an important role in cancer immune evasion. VEGF can enhance immune-suppressive effects in the tumor microenvironment though 3 mechanisms (21), i.e., inhibition of DC maturation to reduce T-cell activation, reduction of T-cell infiltration and increase of inhibitory cells such as...
myeloid derived suppressor cells (MDSCs) and regulatory T cells (Tregs).

TACE is an effective treatment option for intermediate stage (multinodular, preserved liver function and ECOG PS=0) HCC (22–24). However, repeated TACE may lead to liver function impairment and even TACE resistance (25, 26), and TACE alone is unsatisfactory for patients in advanced stage (portal invasion or extrahepatic spread). Therefore, many studies have adopted TACE combined with systemic therapy for the treatment of unresectable HCC (27). TACE combined with sorafenib and lenvatinib, respectively, are commonly used in unresectable HCC (6, 28–30). The possible mechanism is that TACE induces angiogenesis and enhances the serum concentrations of VEGF because of local hypoxia, suggesting that VEGF may exert its greatest antiangiogenic effects before or after TACE (31). More importantly, recent studies found that pre-treatment with molecular targeted agents before TACE can normalize tumor vessels and upregulate VEGF, which may lead to a homogeneous distribution of lipiodol mixed anticancer drugs in the tumors (6). In this study, in order to obtain the best results, all patients received lenvatinib 2 weeks before TACE.

In present study, the ORR was 46.7% (28/60); CR and PR were observed in 4 and 24 patients, respectively. The DOR was 10.0 months (95%CI 9.0-11.0 months). PFS and OS were 13.3 months

![FIGURE 1](image1.png) | Percentage changes from baseline (summed diameters of target tumors by mRECIST).

![FIGURE 2](image2.png) | Kaplan-Meier method-based estimate of DOR by mRECIST.
(95% CI 11.9-14.7 months and 23.6 months (95% CI 22.2-25.0 months), respectively. The median DOR, PFS and OS were longer than reported in previous trials combining PD-1 inhibitors and lenvatinib such as the IMbrave150 study (20) and other clinical trials (19). Therefore, this study showed that TACE combined with lenvatinib plus sintilimab is very effective in unresectable HCC.

This treatment was also safe as shown above. The most common treatment-related AEs were fatigue, hypertension, diarrhea, decreased appetite and Palmar-plantar erythrodysesthesia. In this study, 48%, 5.7% and 3.8% of patients had grade 3, 4 and 5 AEs, respectively. Totally 11.5% of patients discontinued any treatment component because of adverse events, and one individual died.
because of treatment related alimentary tract hemorrhage. The above results were comparable to those reported in previous studies examining combined treatments for unresectable HCC (19, 20, 32, 33), suggesting satisfactory safety and tolerability for this combination.

There were several limitations in this study. Firstly, this was a retrospective trial with a limited sample size, which may lead to potential bias. Besides, most patients in the current study had HBV infection, and prospective multicenter studies with other etiologies are required to validate these findings. Lastly, this was a one-arm study, without a control group. Randomized controlled trials of TACE combined with lenvatinib plus sintilimab versus lenvatinib plus sintilimab should be performed to confirm the efficacy and safety of this regimen.

In conclusion, the objective response rate, duration of response, progression-free survival and overall survival in this study were satisfactory, and adverse events were manageable. Therefore, TACE combined with lenvatinib plus sintilimab is very effective in unresectable HCC.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article.Supplementary material. Further inquiries can be directed to the corresponding authors.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.
**FUNDING**

This study was sponsored by Medicine and Health Discipline Platform Project of Zhejiang Province (2018C019), Medicine and Health Science Project of Zhejiang Province (2020KY483), Project of Hubei Chen Xiaoping Science and Technology Development Foundation (2020XQJH12000008-13) and Science Project of Beijing Medicine and Health Foundation (2020WJJKH04-001LC19004).

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2018) 68(6):394–424. doi: 10.3322/caac.21492

2. European Association for the Study of the Liver, Electronic address, e.e.e and L. European Association for the Study of the. *The EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma*. *J Hepatol* (2018) 69(1):182–236. doi: 10.1016/j.jhep.2018.03.019

3. Villanueva A. Hepatocellular Carcinoma. *N Engl J Med* (2019) 380(15):1450–62. doi: 10.1056/NEJMr1713263

4. Forner A, Reig M, Bruix J. Hepatocellular Carcinoma. *Lancet* (2018) 391(10127):1301–14. doi: 10.S10140-6736(18)30010-2

5. Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial Chemoembolisation Extends Long-Term Survival in Patients With Unresectable Hepatocellular Carcinoma. *Med (Baltimore)* (2018) 97(33):e11872. doi: 10.1097/MD.M.O0000000000011872

6. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, Multicentre Prospective Trial of Transarterial Chemoembolisation (TACE) Plus Sorafenib as Compared With TACE Alone in Patients With Hepatocellular Carcinoma: TACTICS Trial. *Gut* (2020) 69(8):1492–501. doi: 10.1136/gutjnl-2019-318934

7. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, et al. Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Prospective Comparative Study. *Ann Surg Oncol* (2011) 18(2):413–20. doi: 10.1245/s10434-011-1321-8

8. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Pisackla E, et al. Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial. *Lancet* (2018) 391(10126):1163–73. doi: 10.1016/S0140-6736(18)30207-1

9. Hiraoka A, Kuma T, Fukunishi S, Atsukawa M, Hiraoka T, Tsuji K, et al. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib. *Liver Cancer* (2020) 9(1):73–83. doi: 10.1159/000503031

10. Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, et al. Lenvatinib Prolongs the Progression-Free Survival Time of Patients With Intermediate-Stage Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria Analysis. *Cancer Commun (Lond)* (2011) 34:1027–33. doi: 10.1159/000481243

11. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III Study of Sorafenib After Transarterial Chemoembolisation in Japanese and Korean Patients With Unresectable Hepatocellular Carcinoma. *J Clin Oncol* (2018) 36(2):302–10. doi: 10.1200/JCO.2017.764038

12. Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, et al. Adjuvant Transarterial Chemoembolization to Sorafenib in Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. *Cancer Commun (Lond)* (2020) 40(12):743–5. doi: 10.1002/cac2.12110
33. Taylor MH, Lee CH, Makker V, Rasco D, Dutsus CE, Wu J, et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. *J Clin Oncol* (2020) 38(11):1154–63. doi: 10.1200/JCO.19.01598

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cao, Yang, Si, Luo, Zeng, Feng, Chen and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.